Unipharma Co (ROCO:6621) ROCE %: -13.42% (As of Dec. 2025)


ROCO:6621 Unipharma Co Ltd ROCO:6621
74 GF Score
Price NT$11.25
GF Value NT$11.63
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Unipharma Co ROCE %?

Unipharma Co ROCO:6621 +0.90% 74 ROCE % is -13.42% as of Dec. 2025. GuruFocus rates ROCO:6621 with a GF Score™ of 74/100 and a GF Value™ of NT$11.63 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Unipharma Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -13.42%.

Unipharma Co  (ROCO:6621) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Unipharma Co ROCE % Related Terms

Unipharma Co ROCE % Historical Data

* Premium members only.

The historical data trend for Unipharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unipharma Co ROCE % Chart

Unipharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.48 -2.31 -7.07 -8.12 -15.18

Unipharma Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.69 -6.17 -9.73 -17.09 -13.42
ROCO:6621
74GF Score
Unipharma Co Ltd ROCO:6621
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unipharma Co ROCE % Calculation

Unipharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-40.445/( ( (328.976 - 33.152) + (274.994 - 37.937) )/ 2 )
=-40.445/( (295.824+237.057)/ 2 )
=-40.445/266.4405
=-15.18 %

Unipharma Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-33.374/( ( (291.612 - 31.251) + (274.994 - 37.937) )/ 2 )
=-33.374/( ( 260.361 + 237.057 )/ 2 )
=-33.374/248.709
=-13.42 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -13.42% mean?
Unipharma Co (ROCO:6621) has a ROCE % of -13.42% as of Dec. 2025.
Is Unipharma Co's ROCE % too high?
Unipharma Co's current ROCE % is -13.42%. Overall, Unipharma Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's ROCE % compare to ZTS and UTHR?
Unipharma Co's ROCE % of -13.42% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unipharma Co's current ROCE % is -13.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.63, compared to a current price of NT$11.25 — trading 3.3% below its estimated fair value. The current ROCE % is -13.42%. Unipharma Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current ROCE % is -13.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unipharma Co (ROCO:6621) Overvalued in 2026?

Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued. The current stock price of NT$11.25 is trading 3.3% below its estimated GF Value™ of NT$11.63. GuruFocus considers Unipharma Co to be Fairly Valued.

Key valuation signals for ROCO:6621:

  • ROCE %: -13.42%
  • GF Value™: NT$11.63 vs. price of NT$11.25 (3.3% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Unipharma Co Business Description

Address Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
74GF Score

Get the complete analysis for ROCO:6621

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$11.25
Price
NT$11.63
GF Value